Total and Neutralizing Antibody Seroprevalence of Hepatotropic Adeno-Associated Virus Among Healthy and Hemophilia A or B Population from India

HUMAN GENE THERAPY · Published 2025-09-30 · DOI 10.1177/10430342251366208

Authors being retrieved — see the publisher record. https://doi.org/10.1177/10430342251366208

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• High Prevalence of Preexisting Neutralizing Antibodies Against Adeno-Associated Virus Capsids in Mongolian People with Hemophilia · HUMAN GENE THERAPY · 2026 · Cites or is cited by this article · Same journal
• Retroviral Transduction of Human CD4 + T Cells with Membrane-Attached IL-10 Generates Type 1-Like Regulatory T Cells · HUMAN GENE THERAPY · 2026 · Same journal
• Optimization of Alpha-1 Antitrypsin Expression from Adeno-Associated Virus Vectors · HUMAN GENE THERAPY · 2026 · Same journal
• Quantification of Lentiviral Vectors with Nucleic Acid Dyes · HUMAN GENE THERAPY · 2026 · Same journal
• CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences · HUMAN GENE THERAPY · 2026 · Same journal
• A Review of the Challenge of Pre-Existing Humoral Immunity in Adeno-Associated Virus Gene Therapy and Potential Solutions · HUMAN GENE THERAPY · 2026 · Same journal
• Capsid Engineering of Adeno-Associated Viruses for Targeted Gene Therapy in Kidney Diseases · HUMAN GENE THERAPY · 2026 · Same journal
• Ethical and Regulatory Considerations for Developing Gene Therapies Involving Genome Editing · HUMAN GENE THERAPY · 2026 · Same journal
• Helper-Dependent Adenoviral Vectors: Recent Advances and Emerging Applications · HUMAN GENE THERAPY · 2026 · Same journal
• AviNP-Seq: A Blindspot-Free Single-Molecule Framework for Unmasking AAV Genome Heterogeneity and Determining Packaging Limits · HUMAN GENE THERAPY · 2026 · Same journal